Pharming « Terug naar discussie overzicht

Valeant draadje

353 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 ... 14 15 16 17 18 » | Laatste

Omlaag ↓

[verwijderd] 7 april 2016 15:39

Valeant Pharmaceuticals International, Inc. (VRX) -NYSE ? Watchlist

37.59 Up 3.42(10.02%) 9:36AM EDT - Nasdaq Real Time Price

[verwijderd] 7 april 2016 15:40

je zal ze vorige week maar hebben weggedaan.

[verwijderd] 7 april 2016 15:41

mooi nws voor pharm.ze nemen de hele markt over let maar op!

[verwijderd] 7 april 2016 15:44

men legt de nadruk op NOT BLOOD BASED!!!

lucas D 7 april 2016 16:16

Leuk voor een ritje, voor de rest afwachten wat voor zoden het aan de dijk zet.

[verwijderd] 7 april 2016 16:18

Koop advies

Eindelijk

OMHOOG

Peter Markus 7 april 2016 16:37

Die Jasje

BASF en BAYER kopen 7 april 2016 16:39

quote:
Jasje schreef op 7 april 2016 16:18:
Koop advies

Eindelijk

OMHOOG

De analisten van THEODOOR GILISSEN die Pharming al 25 jaar doorlichten/volgen, hebben een VERKOOP advies afgegeven met als KOERSDOEL € 0,00

[verwijderd] 7 april 2016 16:40

die theodoor toch hihih

lucas D 7 april 2016 16:40

Zie dat degene die al langer in Pharming zitten van de gelegenheid gebruik maken om hun aandelen te verkopen, en wie Pharming de laatste mnd. gevolgd heeft begrijpt dat volkomen.

Pharming soms moet je ze hebben maar meestal niet, komt steeds vaker uit.

[verwijderd] 7 april 2016 16:44

je hoeft ze niet te kopen hoor haha, ga je toch lekker wat anders doen met je poen.bye bye

[verwijderd] 10 april 2016 22:10

Valeant CEO Pearson may be held in contempt

Apr 10 2016, 08:18 ET | By: Yoel Minkoff, SA News Editor

More trouble at Valeant Pharmaceuticals (NYSE:VRX)... A Senate committee may soon start contempt proceedings against the drugmaker's chief executive.

"Michael Pearson was under subpoena to appear for a deposition today related to the Senate Special Committee on Aging's drug pricing investigation, and he did not comply with that subpoena," Senators Susan Collins and Claire McCaskill said late Friday. "It is our intent to initiate contempt proceedings against him."

[verwijderd] 10 april 2016 23:24

Big deal, hij gaf geen gehoor aan zn Getuigenoproep.

a writ issued by court authority to compel the attendance of a witness at a judicial proceeding; disobedience may be punishable as a contempt of court

Poepoe minachting van het hof.

[verwijderd] 11 april 2016 21:49

Valeant vraagt topman mee te werken met onderzoek

AMSTERDAM -- Valeant Pharmaceuticals heeft de vertrekkend topman Michael Pearson gevraagd om mee te werken met een onderzoek naar de prijsstelling van medicijnen. Dit maakte de farmaceut maandag bekend.

Pearson liet vrijdag een dagvaarding van een Amerikaanse onderzoekscommissie onbeantwoord. Verschillende onderzoeken lopen in de Verenigde Staten volgens persbureau Reuters tegen Valeant vanwege een "agressieve" prijsstrategie en discutabele boekhoudpraktijken.

Valeant maakte onder CEO Pearson een sterke groei door, gesteund door een flink aantal overnames. Deze transacties gingen volgens Reuters in veel gevallen gepaard met scherpe prijsstijgingen van medicijnen.

Pearson zal vertrekken als bestuursvoorzitter wanneer de farmaceut een vervanger heeft gevonden. Valeant vroeg ook bestuurslid en voormalig financieel directeur Howard Schiller op te stappen, maar dit weigert Schiller.

Het aandeel Valeant Pharmaceuticals noteerde maandag 6,4 procent lager op 31,50 dollar.

Door ABM Financial News. Info@abmfn.nl: +31(0)20-26 28 999

[verwijderd] 12 april 2016 22:53

One of Valeant's creditors not playing ball, calls a default on debt; shares down 6% after hours

Apr 12 2016, 16:38 ET |

Business Insider reports that one of Valeant Pharmaceuticals' (NYSE:VRX) creditors has apparently informed the company that it will call a default on its debt. Shares are down 6% after hours on robust volume.

[verwijderd] 13 april 2016 08:52

quote:
Beur schreef op 12 april 2016 22:53:
One of Valeant's creditors not playing ball, calls a default on debt; shares down 6% after hours

Apr 12 2016, 16:38 ET |

Business Insider reports that one of Valeant Pharmaceuticals' (NYSE:VRX) creditors has apparently informed the company that it will call a default on its debt. Shares are down 6% after hours on robust volume.

Update: In a statement, Valeant reports that it has received a notice of default from holders of its 5.5% Notes due 2023 as a result of the delay in filing its 10-K. If the company files the document by June 11, it will cure the default. Its current target date for filing is April 29 so there appears to be ample time to resolve the issue.

[verwijderd] 14 april 2016 14:44

A Merger And Acquisition/Tax Inversion Idea That Will Probably Never Happen, But Should $VRX
www.seekingalpha.com/article/3965207

Even those who are not avid investors have seen the developments in Valeant Pharmaceuticals International Inc. (NYSE:VRX), as it has been plastered across every newspaper for months now. Valeant is an interesting story. For people unfamiliar with the company's revenue model, it basically grows by acquiring other companies, or the rights to drugs it believes will be successful.
A year after the market crash in 2008, it began a meteoric rise, gaining over 1K% into 2015. But then something astonishing happened. The sketchy and unethical secret life of CEO Michael Pearson started to unravel and become public. The business model also started to show its weaknesses as many drugs failed expectations, or were purchased at close to its peak market cycle.
Valeant's market cap has fallen 87% from last summer and has lost $80 Billion in market cap. Trading at around $260 a share not even a year ago, the stock now trades at $33 a share. The selling pressure is relentless and the stock plummeted over 50% in one day on March 15. The fall was due to Valeant announcing that it reduced earnings and revenue projections, and said that its continuing inability to file its annual financial report could lead to default on $30 billion of debt because of covenants it has with lenders. To make matters worse, many big bondholders are calling for default, the balance sheet is a mess, and the company has come under attack from Andrew Left of Citron Research who is a famed short seller.

Forbes playfully described Valeant's financial statement as "financial-statement gymnastics" and that the "tone at the top of the organization bears too much resemblance to those of Enron, Tyco and WorldCom for comfort."
The situation gets more interesting as famed Hedge Fund Manager Bill Ackman of Pershing Square Capital Management (who owns the largest position in Valeant shares) has muscled his way onto the board, and kicked out the CEO, looking for a suitable replacement. However, it doesn't stop there. Jeffrey Ubben, CEO of the Hedge Fund ValueAct, has disagreed with Ackman over the direction of the company and it now looks as though things might get messy between the two.
But I have an idea for Bill and Jeff: force a potential merger with, or sale to Mallinckrodt PLC (NYSE:MNK).
Mallinckrodt is engaged in the specialty pharmaceuticals business, just like Valeant. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals sector includes branded and generic drugs, and the Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland. I think you know where I am going with this now.
The U.S. Corporate Tax Rate is 35%, one of the highest in the world. This is why many companies have opted for tax inversions to help relocate their headquarters abroad, adopting the [low] tax policies of their new host countries. One of the hottest areas to relocate has been Ireland, which has an extremely low 12.5% rate, making it very business friendly.
There have been many high profile tax inversions and attempts in the last few years. Medtronic (NYSE:MDT) bought Covidien and relocated to Dublin. Walgreens (now Walgreens Boots Alliance WBA) was thinking of moving its headquarters to extremely tax friendly Switzerland, which has a corporate tax rate of 8.5%, but ultimately decided against it, purportedly because it would have cost taxpayers billions of dollars.
The most recent and high profile attempted tax inversion was the mega-merger between Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) which looked ready to go even with public outcry until the US Treasury Department created new rules which would make it harder to invert, leading the deal to be canceled. Although not an inversion, in a similar vein, Apple (NASDAQ:AAPL) holds around 200B in cash owned by Apple's subsidiaries in Knocknaheeny, a rundown northern suburb of Cork, Ireland, and has no plans of repatriating that money because of the huge taxes they would have to pay. That is a shame to me, especially as a shareholder.
Simple fix: lower the tax rate.
If we lowered the US tax rate to somewhere in the range of 20-25%, fewer companies would attempt to invert, more companies would be willing and happy to keep their headquarters in the US, and may even bring cash back to the US.
Pfizer tried to move its headquarters to London in 2014 with its attempted takeover of AstraZeneca plc (NYSE:AZN). Obviously, that didn't pan out for Pfizer. It seems Pfizer has had bad luck lately.
If certain candidates (wink, wink) named Hillary or Bernie are elected, they may raise the corporate tax rate because they think corporations are "too greedy," as Bernie Sanders just did today in reference to the Verizon (NYSE:VZ) strike. This may cause a race to the exits with companies doing whatever they can to relocate abroad. I'm totally opposed to this approach and believe that Trickle Down Economics is the best way to stimulate an economy. But I won't get into the politics of it here.
Mallinckrodt has taken a beating as well because of its similarity with Valeant. Mark Trudeau, the CEO of Mallinckrodt, has stated that Mallinckrodt is not Valeant. He claims they are a strong company, and has pointed to many key factors to explain why he believes his company is positioned for strong growth:
• Net Sales up 20%
• EPS up 17%
• Solid balance sheet and strong FCF
• Raised EPS guidance for the year
He frantically called into CNBC to defend the company after an interview between Melissa Lee and Andrew Left (the same short seller who put out a research note bashing Valeant) created some serious headlines (Left said that "Valeant Looks Like a Choirboy Next to Mallinckrodt"). This was the same kind of language that drove Valeant's shares to fall off a cliff. Some may find his remarks purely malicious; but many of his calls [e.g. Mobileye (NYSE:MBLY), Valeant, and Mallinckrodt), have been right.
You can watch the interview, or should I say sparring match, here.
I believe the merger of Mallinckrodt acquiring Valeant as it continues to become cheaper is a win-win-win-win. It's a win for the major hedge funds, a win for both companies merging, and a win for the shareholders. By merging, there will be cost synergies, they will expand their drug portfolio, will pay less in taxes by relocating its tax headquarters to Ireland, and increase revenue.
Mallinckrodt has boosted their share buyback to $350M, and their main drug Acthar has continued to grow in sales with potential uses for a wide variety of illnesses. The government has made it harder to invert, but it is still possible. In this situation, it might be worth both companies trying to test the new regulations.
Together I believe the new "Valeantckrodt" could become a formidable player in the specialty pharmaceutical arena as it combines similar business models, and Valeant gets the new CEO Ackman is looking for in the form of a new more stable company run by Mark Trudeau.

[verwijderd] 15 april 2016 09:45

Reuters: Valeant turning to investment banks to consider options
Apr 14 2016, 18:54 ET |

Valeant (VRX -2.2%) is up 1.5% after hours as Reuters reports that it's calling in investment banks to go over its options, the clearest signal yet that divestments are coming as it faces down $30B in debt.Goldman Sachs and Centerview Partners are among advisers being consulted.A number of inquiries have come in since CEO Michael Pearson and Pershing Square's Bill Ackman said the firm would consider unloading noncore assets, sources said.Bidders are reportedly kicking the tires on its biggest gastrointestinal product, Xifaxin, as well as aesthetics products Obagi and Solta and skin care product CeraVe.

Het begin van de ontmanteling?

[verwijderd] 19 april 2016 11:12

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research note issued on Friday, Analyst Ratings Network.com reports.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 33.34 on Friday. Valeant Pharmaceuticals Intl has a 1-year low of $25.27 and a 1-year high of $263.81. The stock has a market cap of $11.44 billion and a PE ratio of 19.15. The stock’s 50 day moving average is $41.89 and its 200-day moving average is $87.61.

Valeant Pharmaceuticals Intl (NYSE:VRX) last released its earnings results on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 earnings per share for the quarter, missing the consensus estimate of $2.61 by $0.11. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.75 billion. During the same period last year, the firm posted $2.58 EPS. Valeant Pharmaceuticals Intl’s revenue was up 22.3% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.79 EPS for the current fiscal year.

Several hedge funds and institutional investors recently modified their holdings of VRX. Paulson & CO. Inc. boosted its position in shares of Valeant Pharmaceuticals Intl by 49.2% in the fourth quarter. Paulson & CO. Inc. now owns 13,265,900 shares of the specialty pharmaceutical company’s stock worth $1,348,479,000 after buying an additional 4,375,900 shares during the last quarter. Brahman Capital Corp. boosted its position in shares of Valeant Pharmaceuticals Intl by 102.3% in the fourth quarter. Brahman Capital Corp. now owns 8,117,753 shares of the specialty pharmaceutical company’s stock worth $825,170,000 after buying an additional 4,104,202 shares during the last quarter. Norges Bank bought a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $264,897,000. Price T Rowe Associates Inc. MD boosted its position in shares of Valeant Pharmaceuticals Intl by 9.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 21,853,814 shares of the specialty pharmaceutical company’s stock worth $2,220,949,000 after buying an additional 1,806,903 shares during the last quarter. Finally, Iridian Asset Management LLC CT boosted its position in shares of Valeant Pharmaceuticals Intl by 59.2% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,324,602 shares of the specialty pharmaceutical company’s stock worth $439,596,000 after buying an additional 1,607,834 shares during the last quarter.

VRX has been the subject of several other research reports. RBC Capital reiterated a “sector perform” rating and set a $65.00 target price (down previously from $69.00) on shares of Valeant Pharmaceuticals Intl in a research note on Monday, April 11th. JPMorgan Chase & Co. restated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, March 16th. TD Securities lowered shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating and lowered their price target for the stock from $155.00 to $110.00 in a research report on Monday, February 29th. Deutsche Bank restated a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, March 2nd. Finally, Rodman & Renshaw restated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, March 22nd. Seven research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $90.44.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Micky Masi 19 april 2016 11:25

Al die adviezen hadden ze een jaar geleden moeten geven. Achteraf is makkelijk!!

353 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 ... 14 15 16 17 18 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	18 apr 2024 12:24
Koers	0,887
Verschil	-0,074 (-7,65%)
Hoog	0,957
Laag	0,861
Volume	21.417.592
Volume gemiddeld	6.382.260
Volume gisteren	2.891.437

Pharming nieuws meer

08:29	Pharming vervangt converteerbare lening	5
08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...	2
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...	2
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1
14 feb	Video-update: AEX index, Brunel en Ph...
20 jan	RTW verkleint belang in Pharming	6